摘要
The assessment of resectability,as well as the optimal induction treatment to achieve secondary resectability in patients with colorectal cancer liver metastases(CRLM)remain debated.Bond et al.(1)recently presented the results of CAIRO5 trial in Lancet Oncology,comparing different chemotherapy regimens for initially unresectable CRLM.
